Myovant Sciences Ltd Stock News

Myovant Sciences to hold a pharmacetical update conference call MYOV

Myovant Sciences Ltd:

Myovant Sciences (NYSE:MYOV) is up 7% premarket on light volume in reaction to positive results from a Phase 3 clinical trial, SPIRIT 2, evaluating once-daily relugolix combo therapy (relugolix 40 m

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Ar

Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix as a treatment for advanced prostate cancer.

Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix as a treatment for advanced prostate cancer.

Myovant Sciences says co-primary endpoints met in Phase 3 SPIRIT 2 study MYOV

Myovant Sciences (MYOV), a healthcare company focused on redefining care for women's health and prostate cancer, today announced that SPIRIT 2, the first of two Phase 3 studies of once-daily relugolix

Co-primary endpoints met with 75.2% response rate for dysmenorrhea (menstrual pain) (p < 0.0001) and 66.0% response rate for non-menstrual pelvic pain...

Myovant Sciences Ltd (NYSE:MYOV) major shareholder Chemical Co. Ltd. Sumitomo acquired 70,000 shares of the company’s stock in a transaction on Friday, April 17th. The shares were acquired at an ave

Myovant Sciences Ltd (NYSE:MYOV) major shareholder Chemical Co. Ltd. Sumitomo bought 50,300 shares of the stock in a transaction that occurred on Monday, April 20th. The stock was acquired at an avera

Filing thousands of pages of data electronically from remote locations as employees sheltered in place against COVID-19, Myovant Sciences asked regulators Tuesday to quickly approve its once-a-day pil

BASEL, Switzerland, April 21, 2020 -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women's health and prostate cancer, today announced it.

BASEL, Switzerland, April 21, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women's health...

Myovant Sciences (NYSE:MYOV) has submitted a marketing application to the FDA seeking approval to use oral relugolix (120 mg) to treat men with advanced prostate cancer.It plans to file another applic